Zenas BioPharma Inc.

ZBIO | NASDAQ

Price Alert Chart Builder DCF Calculator

$25.93

-$2.53 (-8.89%)

At close: Nov 5, 2026, 4:00 PM ET

$25.00

-$0.93 (-3.59%)

After-hours: Nov 5, 2026, 5:09 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $1.69B

Enterprise Value $1.6B

Beta -1.02

Average Volume 767.37K

Shares Outstanding (Diluted) 63.11M

Shares Change YoY 50.75%

Institutional Ownership N/A

Exchange NASDAQ

ISIN US98937L1052

Price Performance

Price Change 1M -3.8%

Price Change 3M -19.4%

Price Change 6M 34.6%

Price Change YTD -28.6%

Price Change 1Y -20.1%

Price Change 3Y N/A

Price Change 5Y N/A

1M CAGR (ann.) -15.2%

1Y CAGR (ann.) -7.6%

5Y CAGR (ann.) N/A

All-Time CAGR 22.4%

Valuation

PE Ratio -2.96

Forward PE N/A

PEG Ratio 0.03

Forward PEG -0.08

PS Ratio 1,854.93

Forward PS 32.00

PB Ratio 7.51

P/FCF Ratio -8.21

P/Adj. FCF Ratio -7.17

P/OCF Ratio -7.95

EV/Sales 1,601.40

EV/EBIT -3.50

EV/EBITDA -3.50

EV/FCF -7.09

Earnings Yield -33.8%

FCF Yield -12.2%

Adj. FCF Yield -13.9%

Financial Health

Net Cash $253.55M

Total Debt $389.6M

Cash & Short-Term Investments $643.13M

Total Assets $701.69M

Current Ratio 9.93

Quick Ratio 9.93

Debt / Equity Ratio 1.58

Debt / EBITDA -0.85

Debt / FCF -1.72

OCF / Debt -0.58

Interest Coverage -28.09

Altman Z-Score -0.61

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin -5972.6%

Operating Profit Margin -47557.3%

EBITDA Margin -45728.0%

Net Profit Margin -48438.4%

FCF Margin -22597.4%

Adj. FCF Margin -25870.4%

SBC / Revenue 3273.0%

SBC Impact (per share) -14.5%

Returns

Return on Assets -69.0%

Return on Equity -189.7%

Return on Invested Capital -74.7%

Return on Capital Employed -74.8%

Return on Tangible Assets -69.0%

Historical Growth (CAGR)

Revenue CAGR 3Y -111.4%

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y -70.0%

EPS CAGR 5Y N/A

EPS CAGR 10Y N/A

FCF CAGR 3Y -70.7%

FCF CAGR 5Y N/A

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 5

EPS Growth Next 3Y 26.6%

Revenue Growth Next 3Y 604.9%

Earnings Date Nov 18, 2026

EPS Estimate (next Q) -$1.24

EPS Growth Est (next Q) 1.6%

Revenue Est (next Q) $1.01M

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $43.50

Price Target Upside 52.8%

Cash Flow

Operating Cash Flow $-225.97M

Free Cash Flow $-225.97M

Adj. Free Cash Flow $-258.7M

FCF Per Share -$3.58

OCF Per Share -$3.58

OCF/S Ratio -22597.2%

Income Statement

Revenue $1M

Gross Profit $-59.73M

Operating Income $-475.57M

EBITDA $-457.28M

Net Income $-484.38M

EPS (Diluted) -$9.62

Revenue / Employee $5.99K

Profit / Employee $-2.9M

Employees 167